Page last updated: 2024-09-04

docetaxel anhydrous and phosphomannopentaose sulfate

docetaxel anhydrous has been researched along with phosphomannopentaose sulfate in 2 studies

Compound Research Comparison

Studies (docetaxel anhydrous)	Trials (docetaxel anhydrous)	Recent Studies (post-2010) (docetaxel anhydrous)	Studies (phosphomannopentaose sulfate)	Trials (phosphomannopentaose sulfate)	Recent Studies (post-2010) (phosphomannopentaose sulfate)
12,110	3,216	6,920	61	8	13

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Addison, R; Basche, M; Chow, LQ; Creese, BR; Davis, K; Eckhardt, SG; Gore, L; Grolnic, S; Gustafson, DL; Holden, SN; Morrow, MC; O'Bryant, CL; Roberts, KL	1
Begbie, S; Boyce, A; de Souza, P; Harvie, R; Khasraw, M; Lim, V; Marx, G; McCowatt, S; Parnis, F; Pavlakis, N; Underhill, C	1

Trials

2 trial(s) available for docetaxel anhydrous and phosphomannopentaose sulfate

Article	Year
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer chemotherapy and pharmacology, 2008, Volume: 63, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fibroblast Growth Factor 2; Gastrointestinal Diseases; Glucuronidase; Heparin; Humans; Male; Maximum Allowable Concentration; Middle Aged; Neoplasm Proteins; Neoplasms; Oligosaccharides; Partial Thromboplastin Time; Platelet Factor 4; Taxoids; Vascular Endothelial Growth Factor A	2008
Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:6 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Dose-Response Relationship, Drug; Glucuronidase; Humans; Male; Middle Aged; Neoplasm Metastasis; Oligosaccharides; Prostatic Neoplasms; Taxoids; Treatment Failure	2010

Article

Year

A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.

Cancer chemotherapy and pharmacology, 2008, Volume: 63, Issue:1

Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fibroblast Growth Factor 2; Gastrointestinal Diseases; Glucuronidase; Heparin; Humans; Male; Maximum Allowable Concentration; Middle Aged; Neoplasm Proteins; Neoplasms; Oligosaccharides; Partial Thromboplastin Time; Platelet Factor 4; Taxoids; Vascular Endothelial Growth Factor A

2008

Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:6

Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Dose-Response Relationship, Drug; Glucuronidase; Humans; Male; Middle Aged; Neoplasm Metastasis; Oligosaccharides; Prostatic Neoplasms; Taxoids; Treatment Failure

2010